Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

Official Title

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

Summary:

B-cell maturation antigen (BCMA) is a target present on tumour cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Trial Description

Primary Outcome:

  • DE Phase: Number of participants achieving dose limiting toxicities (DLT)
  • DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
  • DE Phase: Number of participants with abnormality in vital signs
  • DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters
  • CE Phase: Number of participants achieving Overall Response Rate (ORR)
Secondary Outcome:
  • DE Phase: Number of participants achieving ORR
  • CE Phase: Number of participants achieving Clinical Benefit Rate (CBR)
  • DE Phase and CE Phase: Number of participants achieving Partial Response
  • DE Phase and CE Phase: Number of participants achieving Very Good Partial Response (VGPR)
  • DE Phase and CE Phase: Number of participants achieving Complete Response (CR)
  • DE Phase and CE Phase: Number of participants achieving stringent Complete Response (sCR)
  • DE Phase and CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments
  • DE Phase and CE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: GSK3359609 concentration when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Concentration of anti-drug antibodies (ADAs) against belantamab mafodotin when administered in combination with anti-cancer treatments
  • DE Phase and CE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Concentration of ADAs against GSK3359609 when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin
  • DE Phase and CE Phase: Number of participants with adverse events of special interest (AESI)
  • DE Phase and CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination
  • CE Phase: Number of participants achieving Progression-free survival (PFS)
  • CE Phase: Duration of response (DoR)
  • CE Phase: Time to response (TTR)
  • CE Phase: Number of participants achieving Overall survival (OS)
  • CE Phase: Number of participants with AEs and SAEs
  • CE Phase: Number of participants with AEs leading to discontinuation
  • CE Phase: Number of participants with dose reduction or delay
  • CE Phase: Number of participants with abnormality in vital signs
  • CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society